Published in BMC Cardiovasc Disord on January 28, 2017
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation (2002) 76.93
International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care (2009) 26.77
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med (1996) 23.76
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07
Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation (2003) 8.29
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01
Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med (2009) 6.62
Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 4.94
DS14: standard assessment of negative affectivity, social inhibition, and Type D personality. Psychosom Med (2005) 3.55
A prospective study of diet quality and mortality in women. JAMA (2000) 2.52
Temporal trends in revascularization strategy and outcomes in left main coronary artery stenosis: data from the ASAN Medical Center-Left MAIN Revascularization registry. Circ Cardiovasc Interv (2015) 2.03
Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol (2013) 1.95
Biomarkers: potential uses and limitations. NeuroRx (2004) 1.86
What are biomarkers? Curr Opin HIV AIDS (2010) 1.80
Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics. J Am Coll Cardiol (2015) 1.66
Personality and mortality after myocardial infarction. Psychosom Med (1996) 1.59
Type D personality is unrelated to major adverse cardiovascular events in patients with coronary artery disease treated by intracoronary stenting. Ann Behav Med (2014) 1.42
EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). Eur Heart J (2015) 1.40
Anger and hostility predict the development of atrial fibrillation in men in the Framingham Offspring Study. Circulation (2004) 1.40
Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart (2006) 1.38
Increased anxiety and depression in Danish cardiac patients with a type D personality: cross-validation of the Type D Scale (DS14). Int J Behav Med (2009) 1.10
Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. World J Biol Chem (2015) 0.99
Biomarkers: current perspectives and future prospects. Expert Rev Mol Diagn (2003) 0.98
Prevalence of "distressed" personality in patients with coronary artery disease and its correlation with morbidity after coronary surgery. Hellenic J Cardiol (2013) 0.85
Hostility may explain the association between depressive mood and mortality: evidence from the French GAZEL cohort study. Psychother Psychosom (2010) 0.83
Method of test administration as a factor in test validity: the use of a personality questionnaire in the prediction of cancer and coronary heart disease. Behav Res Ther (1995) 0.80
Prognostic importance of distressed (Type D) personality and shocks in patients with an implantable cardioverter defibrillator. Int J Cardiol (2012) 0.79
Determinants for achieving the LDL-C target of lipid control for secondary prevention of cardiovascular events in Taiwan. PLoS One (2015) 0.79
A novel SNP associated with nighttime pulse pressure in young-onset hypertension patients could be a genetic prognostic factor for cardiovascular events in a general cohort in Taiwan. PLoS One (2014) 0.77
The validity of the Type D construct and its assessment in Taiwan. BMC Psychiatry (2013) 0.76
Determinants for achieving the LDL-C target of lipid control for secondary prevention of cardiovascular events in Taiwan. PLoS One (2015) 0.79
Challenges and solutions in medically managed ACS in the Asia-Pacific region: expert recommendations from the Asia-Pacific ACS Medical Management Working Group. Int J Cardiol (2014) 0.78
Guideline-adherent therapy in patients with cardiovascular diseases in Taiwan. J Formos Med Assoc (2013) 0.76
Association of low serum albumin concentration and adverse cardiovascular events in stable coronary heart disease. Int J Cardiol (2017) 0.75
Circulating fatty-acid binding-protein 4 levels predict CV events in patients after coronary interventions. J Formos Med Assoc (2020) 0.75
Residual Risk Factors to Predict Major Adverse Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with and without Diabetes Mellitus. Sci Rep (2017) 0.75
Pharmacogenetic dosing of warfarin in the Han-Chinese population: a randomized trial. Pharmacogenomics (2017) 0.75
Optimal achieved blood pressure for patients with stable coronary artery disease. Sci Rep (2017) 0.75